ETI 201

Drug Profile

ETI 201

Alternative Names: ETI 104

Latest Information Update: 05 Dec 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Elusys Therapeutics
  • Class Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Systemic lupus erythematosus

Most Recent Events

  • 23 Mar 2004 ETI 201 is available for licensing (http://www.elusys.com/)
  • 09 Jul 2003 Data presented at the Annual European Congress of Rheumatology (EULAR-2003) have been added to the adverse events and Immunological Disorders pharmacodynamics section
  • 24 Jun 2003 Clinical data from a media release have been added to the adverse events and Immunological Disorders pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top